5-Amino-1MQ vs AOD-9604 · Mechanism, Dose, Cited Research

Side-by-side

	5-Amino-1MQ	AOD-9604
Mechanism	NNMT inhibitor; preserves methyl donors, elevates NAD+.	hGH fragment (176-191); β-adrenergic-independent lipolysis.
Half-life	Oral bioavailability; daily dosing.	Short (SC).
Dose	2-5 mg oral daily.	300 mcg daily SC (fasted).
Cycle	8-12 weeks.	12 weeks on / 4 off.
Research context	Preclinical obesity reversal in mouse models¹; limited human data.	Preclinical lipolysis without affecting IGF-1².
Cost tier	Mid (oral supply).	Low-to-mid.

5-Amino-1MQ and AOD-9604 both appear in body-recomposition research, but the biology is different. 5-Amino-1MQ is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme over-expressed in adipose tissue in obesity¹. Inhibiting NNMT preserves SAM and other methyl donors, elevates cellular NAD+, and in preclinical mouse models reverses diet-induced obesity. It is not a peptide; it is a small organic molecule, which matters for administration route (oral).

AOD-9604 is a 16-amino-acid fragment of the C-terminus of human growth hormone (residues 176-191), investigated for lipolytic activity². The mechanism is characterised as β-adrenergic-independent lipolysis: it drives fat breakdown without the cardiovascular stimulation of classical β-agonists. Research protocols use daily subcutaneous dosing in the fasted state. Preclinical data suggest selective lipolysis without affecting IGF-1.

Human clinical data is limited for both. 5-Amino-1MQ has strong preclinical data but little human-trial data. AOD-9604 has older preclinical data and some early-stage human-trial data that did not establish strong efficacy. Research-protocol selection depends on the mechanism of interest: NAD+ metabolism and methyl-donor biology favours 5-Amino-1MQ; hGH-fragment lipolysis favours AOD-9604. See 5-Amino-1MQ NNMT inhibition deep-dive and AOD-9604 lipolysis research.

Frequently asked

Is 5-Amino-1MQ actually a peptide?

No. It is a small-molecule NNMT inhibitor, not a peptide. Research suppliers group it with peptides because its use-case overlaps (body-recomposition research), but the chemistry is different.

Is AOD-9604 proven to burn fat in humans?

Preclinical data is supportive but early-stage human trials did not establish strong weight-loss efficacy compared to placebo. Current research use should treat it as mechanism-of-interest rather than established weight-loss therapy.

Can they be combined?

Mechanisms do not overlap, so combination is mechanistically coherent. Both are research-phase compounds with limited human safety data, so combination should be cautious.

Research desk

Ordering both 5-Amino-1MQ and AOD-9604 for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.

Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

Comparison Melanotan-II vs PT-141 Melanotan-II vs PT-141: non-selective melanocortin agonist vs selective MC4-receptor agonist (bremelanotide). Melanogenesis vs libido research.

References

Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of NNMT reverse high-fat-diet-induced obesity in mice. Biochem Pharmacol. 2018. PMID: 29155147
Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. 2001. PMID: 11713213

All references verified against PubMed via NCBI E-utilities.